Research map: Efficacy and safety of transarterial chemoembolization combined with donafenib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus: a dual-center, retrospective propensity score-matched analysis

Back to the article

Papers in this map

  1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries · Hyuna Sung · 2021 · 114646 citations · Cited by this paper
  2. A review of soluble mediator and cytokine networks linking combination immunotherapy, tumor microenvironment remodeling and skeletal muscle dysfunction · 2026 · Related
  3. Management of Hepatocellular Carcinoma: An Update Δσ · Jordi Bruix · 2011 · 8176 citations · Cited by this paper
  4. GFI1 as a novel regulator of γδ T cell development and the IL-17/IFN-γ lineage commitment · 2026 · Related
  5. Hepatocellular carcinoma · Alejandro Forner · 2018 · 5718 citations · Cited by this paper
  6. HIF-1α-centered metabolic reprogramming in osteoarthritis: cell type-specific effects and intercellular crosstalk among chondrocytes, BMSCs, and macrophages · 2026 · Related
  7. Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference · Jordi Bruix · 2001 · 4098 citations · Cited by this paper
  8. Acquired immune-mediated thrombotic thrombocytopenic purpura with severe cholestatic liver injury and reversible acute kidney injury after ivonescimab-containing chemoimmunotherapy: a case report and literature review · 2026 · Related
  9. Hepatocellular carcinoma · Alejandro Forner · 2012 · 4059 citations · Cited by this paper
  10. Lipoprotein (a) fuels EV71 replication by activating p38 MAPK-autophagy axis · 2026 · Related
  11. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial · Josep Maria Llovet · 2002 · 3529 citations · Cited by this paper
  12. Delivery platforms for in vivo CAR-T engineering · 2026 · Related
  13. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib · Thomas C. C. Yau · 2020 · 1278 citations · Cited by this paper
  14. Envafolimab – novel anti-PD-1/PD-L1 antibody in cancer treatment · 2026 · Related
  15. CTCAE versión 5.0. Evaluación de la gravedad de los eventos adversos dermatológicos de las terapias antineoplásicas · Azael Freites‐Martínez · 2020 · 900 citations · Cited by this paper
  16. Integrated plasma proteomics identifies HLA-G and osteopontin as circulating biomarkers of resistance to PD-1 inhibitor plus chemotherapy in choriocarcinoma · 2026 · Related
  17. Some Methods of Propensity‐Score Matching had Superior Performance to Others: Results of an Empirical Investigation and Monte Carlo simulations · Peter C. Austin · 2009 · 781 citations · Cited by this paper
  18. Contribution of monocyte subpopulations to the pathogenesis and therapy outcome of type 1 diabetes management in pediatric patients · 2026 · Related
  19. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study · Shukui Qin · 2023 · 732 citations · Cited by this paper
  20. mRECIST for HCC: Performance and novel refinements · Josep Maria Llovet · 2020 · 694 citations · Cited by this paper
  21. Tumor Size Predicts Vascular Invasion and Histologic Grade · Timothy Michael Pawlik · 2005 · 644 citations · Cited by this paper
  22. Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition) · Jian Zhou · 2023 · 476 citations · Cited by this paper
  23. Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial · Shukui Qin · 2021 · 425 citations · Cited by this paper
  24. Camrelizumab: First Global Approval · Anthony Markham · 2019 · 274 citations · Cited by this paper
  25. A new classification for hepatocellular carcinoma with portal vein tumor thrombus · Jie Shi · 2010 · 190 citations · Cited by this paper
  26. Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide · Do Young Kim · 2024 · 163 citations · Cited by this paper
  27. Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers · Lucia Cerrito · 2019 · 148 citations · Cited by this paper
  28. Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy · Caicun Zhou · 2021 · 132 citations · Cited by this paper
  29. Donafenib: First Approval · Susan J. Keam · 2021 · 115 citations · Cited by this paper
  30. Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong · TT Cheung · 2006 · 90 citations · Cited by this paper
  31. Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study · Liyun Zheng · 2021 · 90 citations · Cited by this paper
  32. Comprehensive treatments for hepatocellular carcinoma with portal vein tumor thrombosis · Jincheng Wang · 2018 · 52 citations · Cited by this paper
  33. Multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus - Eastern Hepatobiliary Surgical Hospital consensus statement · Shuqun Cheng · 2016 · 51 citations · Cited by this paper
  34. Portal vein tumor thrombus is a bottleneck in the treatment of hepatocellular carcinoma · Sun Juxian · 2016 · 48 citations · Cited by this paper
  35. Actual long-term survival in HCC patients with portal vein tumor thrombus after liver resection: a nationwide study · Zhenhua Chen · 2020 · 47 citations · Cited by this paper
  36. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience · Laihui Luo · 2022 · 41 citations · Cited by this paper
  37. Impact of Performance Status on Response and Survival Among Patients Receiving Checkpoint Inhibitors for Advanced Solid Tumors · Mridula Krishnan · 2021 · 33 citations · Cited by this paper
  38. Donafenib in hepatocellular carcinoma · Rusi Chen · 2023 · 30 citations · Cited by this paper
  39. [Chinese clinical practice guidelines for transarterial chemoembolization of hepatocellular carcinoma (2023 edition)]. · 2023 · 30 citations · Cited by this paper

Source: OpenAlex (CC0)